A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
Annals of Neurology
The article by Ponsen and colleagues 1 and the accompanying editorial by Stern 2 point out the importance of preclinical detection of risk for subsequent development of Parkinson's disease. The interesting work by Ponsen and colleagues 1 would suggest that tests of olfactory function, alone or in combination with other tests, may play a role in developing prognosticating tests. We developed such a test that, when applied prospectively to 212 subjects with symptoms suggestive but not diagnosticdoi:10.1002/ana.20353 fatcat:mv55peegjvbolkpupcpb22wwza
more »... f Parkinson's disease, was able to detect 40 of the 59 subjects subsequently diagnosed with Parkinson's disease over a 2-year period. 3,4 Also, the test battery, using tests of olfaction, motor speed, and depression, was able to predict 37 of 40 subjects in whom Parkinson's disease subsequently was clinically excluded. The test battery was 92% specific and 68% sensitive with an area of the receiver operator characteristics curve of 0.88. Olfactory testing alone had a sensitivity of 82% and a specificity of 81%. Developing any diagnostic or prognostic test is complicated. In addition to specificity and sensitivity, prior probabilities (prevalence of those at risk) are a major factor. For example, the prevalence of persons at risk for Parkinson's disease in a population of concern (such as first-degree relatives or those with specific environmental exposures) would have to be nearly 18% for olfactory testing to have a 50% positive and negative predictive value. Even at this, there would be as many false-positives and false-negatives as true-positives and true-negatives. Often little attention is given to the anticipated prevalence rates of those at risk when discussing potential diagnostic or predictive tests. Combining multiple tests into a diagnostic or prognostic battery to improve specificity and sensitivity is problematic. 3
Coastal Structures 2007
Stive 5 nd Author: Henk Jan Verhagen Stone stability Bed protection Bed damage Stone entrainment Bed load transport Turbulence Decelerating flow Open-channel flow ... α = 3.5 (for WL Ψ ) and α = 3.0 (for KEYWORDS -CSt07 Abstract acceptance number: 204 STONE STABILITY UNDER DECELERATING OPEN- CHANNEL FLOW 1 st Author: Nguyen Thanh Hoan 2 nd Author: Rob Booij ...doi:10.1142/9789814282024_0126 fatcat:q6eoej5bgjbadjgxotnscv5mhy
Stones often move when an increased u-velocity fluid package reaches the bed (Hofland and Booij, 2004; De Ruijter, 2004) . ...doi:10.1061/(asce)hy.1943-7900.0000387 fatcat:wtwdu3f4sfd5vpbs3vm26zf4xm
Currently, 123 I-FP-CIT SPECT is used in clinical practice to determine nigrostriatal dysfunction in Parkinson's disease (PD) and to differentiate PD from other tremor disorders (Booij et al., 1999) . ...doi:10.1016/j.nicl.2014.05.003 pmid:25068111 pmcid:PMC4110352 fatcat:szzxt5ot25g3jhkk3pwlvt47qa
Dopamine D 2/3 receptor (D 2/3 R) agonist radiopharmaceuticals are considered superior to antagonists to detect dopamine release, e.g. induced by amphetamines. Agonists bind preferentially to the high-affinity state of the dopamine D 2 R, which has been proposed as the reason why agonists are more sensitive to detect dopamine release than antagonist radiopharmaceuticals, but this theory has been challenged. Interestingly, not all agonists similarly activate the classic cyclic adenosine monodoi:10.1186/s13550-014-0053-3 pmid:25977878 pmcid:PMC4422956 fatcat:vtzx5uiemray5klk5e6vx266oq
more »... phate (cAMP) and the β-arrestin-2 pathway, some stimulate preferentially one of these pathways; a phenomenon called biased agonism. Because these pathways can be affected separately by pathologies or drugs (including dopamine releasers), it is important to know how agonist radiotracers act on these pathways. Therefore, we characterized the intracellular signalling of the well-known D 2/3 R agonist radiopharmaceuticals NPA and PHNO and of several novel D 2/3 R agonists. Methods: cAMP accumulation and β-arrestin-2 recruitment were measured on cells expressing human D 2 R. Results: All tested agonists showed (almost) full agonism in both pathways. Conclusions: The tested D 2/3 R agonist radiopharmaceuticals did not exhibit biased agonism in vitro. Consequently, it is likely that drugs (including psychostimulants like amphetamines) and/or pathologies that influence the cAMP and/or the β-arrestin-2 pathway may influence the binding of these radiopharmaceuticals.
We used the thalamus as a proxy of citalopram-induced changes in brain SERT here, because it shows the most reliable binding potential measurements for this ligand ( Booij et al., 2007 ) . ... We here focused on thalamic SERT, as the thalamus provides the most reliable estimate of SERT occupancy using [ 123 I]FP-CIT SPECT ( Booij et al., 2007 ) , but we acknowledge interregional variation in ...doi:10.1016/j.euroneuro.2018.07.099 pmid:30082141 fatcat:zfdfttnxfjhpjlwzgd7w7uwhye
22q11 Deletion syndrome (22q11DS) is associated with chromosome 22q11 microdeletions and high rates of psychiatric disorders. Susceptibility for these disorders could be explained by haploinsufficiency of the catechol-O-methyltransferase gene, which encodes an enzyme involved in dopamine (DA) breakdown. It is unknown how dopaminergic neurotransmission is affected in people with 22q11DS. To date, there have been no controlled studies investigating dopaminergic neurotransmission in people withdoi:10.1038/sj.npp.1301508 pmid:17653112 fatcat:52rihpjlrrejbodpbnj5qgym2u
more »... 11DS. We report the results of a challenge study in high-functioning adults with 22q11DS and age-and gender-matched controls using neuro-endocrine and peripheral dopaminergic markers. At baseline, 22q11DS subjects compared to controls had higher urine DA levels and lower plasma levels of the predominant DA metabolite homovanillic acid (HVA). Following DA depletion, 22q11DS subjects showed lower urine and plasma HVA levels and a lower prolactin response than controls. The ratio of DA/HVA, a rough index of DA turnover, was significantly higher in the 22q11DS subjects at baseline and after DA depletion. Our results suggest that adults with 22q11DS have disrupted dopaminergic neurotransmission, which might explain their susceptibility for psychiatric disorders.
Huntington's disease (HD) is a fatal neurodegenerative disease caused by a CAG expansion mutation in the huntingtin gene. As a result, intranuclear inclusions of mutant huntingtin protein are formed, which damage striatal medium spiny neurons (MSNs). A review of Positron Emission Tomography (PET) studies relating to HD was performed, including clinical and preclinical data. PET is a powerful tool for visualisation of the HD pathology by non-invasive imaging of specific radiopharmaceuticals,doi:10.3390/molecules25030482 pmid:31979301 pmcid:PMC7038198 fatcat:bwhvj3moyvb7dlucjrlservu3a
more »... h provide a detailed molecular snapshot of complex mechanistic pathways within the brain. Nowadays, radiochemists are equipped with an impressive arsenal of radioligands to accurately recognise particular receptors of interest. These include key biomarkers of HD: adenosine, cannabinoid, dopaminergic and glutamateric receptors, microglial activation, phosphodiesterase 10 A and synaptic vesicle proteins. This review aims to provide a radiochemical picture of the recent developments in the field of HD PET, with significant attention devoted to radiosynthetic routes towards the tracers relevant to this disease.
(Booij et al., 1999) . ... et al., 1997 (Booij et al., , 1998 . before SPECT imaging. ... Booij, J., Habraken, J.A., Bergmans, P., Tissingh, G., Winogrodzka, A., Wolters, E.C., Janssen, A.M., Stoof, J.C., van Three patients in this study were found to have Royen, E.A., 1998 Conclusion ...doi:10.1016/s0920-9964(00)00023-2 pmid:11163545 fatcat:hha7dnftzvfqled6mqt3cu2irq
Crunelle, Wim van den Brink, Geert Dom and Jan Booij Summary Impulsivity is a multidimensional construct, including impulsive decision-making and impulsive action, representing relatively independent neurocircuitries ...doi:10.1192/bjp.bp.113.132977 pmid:24676965 fatcat:rrlcivgb3vg5lkrpwavlmowcp4
The purpose of this review is to examine whether a contribution of social exclusion to the pathogenesis of psychosis is compatible with the dopamine hypothesis and/or the neurodevelopmental hypothesis. Humans experience social exclusion as defeating. An animal model for defeat is the resident-intruder paradigm. The defeated animal shows evidence of an increased sensitivity to amphetamine, increased dopamine release in the nucleus accumbens and prefrontal cortex, and increased firing ofdoi:10.1093/schbul/sbw180 pmid:28053019 pmcid:PMC5782499 fatcat:lc6histuk5c7hjphpp3bh7x65u
more »... gic neurons in the ventral tegmental area. As for humans, one study showed that amphetamine-induced striatal dopamine release was significantly greater among nonpsychotic young adults with severe hearing impairment than among normal hearing controls. Two other studies reported an association between childhood trauma and increased dopamine function in striatal subregions. Several studies have suggested that the perigenual anterior cingulate cortex (pgACC) may play a role in the processing of social stress. Importantly, the pgACC regulates the activity of the ventral striatum through bidirectional interconnections. We are not aware of studies in humans that examined whether (proxies for) social exclusion contributes to the structural brain changes present at psychosis onset. Animal studies, however, reported that long-term isolation may lead to reductions in volume of the total brain, hippocampus, or medial prefrontal cortex. Other animal studies reported that social defeat can reduce neurogenesis. In conclusion, the answer to the question as to whether there are plausible mechanisms whereby social exclusion can contribute to the pathogenesis of psychosis is cautiously affirmative.
.; Booij, J.; Reneman, L. Dexamphetamine (dAMPH) is a stimulant drug that is widely used recreationally as well as for the treatment of attention-deficit hyperactivity disorder (ADHD). ... FUNDING AND DISCLOSURE Jan Booij is a consultant for GE Healthcare on the use of DAT imaging, educational matters and received a research grant from the company. ... in [ 123 I]IBZM BP ND was expressed as a % of the pre-dAMPH BP ND (Booij et al, 1997) . ...doi:10.1038/npp.2014.301 pmid:25394786 pmcid:PMC4367461 fatcat:ucbadzj3s5gidoikkpdij4brja
.; Booij, J.; Habraken, J.; de Munck, J.C.; van Herk, M.; Verbeeten, B.; van Royen, E.A. ...doi:10.1007/bf00841396 pmid:9169565 fatcat:bgpinmriabfazgnhjrkpmz4ds4
The only study that looked into 5-HT synthesis reported on a decreased [ 11 C]AMT trapping in frontal regions in males, but not in women (Booij et al. 2014) . ... simple ratio methods were used in the SERT SPECT studies, which are more prone to changes in tracer delivery, whereas modelling time activity curves were used in some PET studies (e.g. the study of Booij ...doi:10.1007/s00213-016-4396-5 pmid:27568200 pmcid:PMC5021729 fatcat:chu6pnz525f65c7fijuoj5pkiu
ORCID iDs Anouk Schrantee https://orcid.org/0000-0002-4035-4845 Henk-Jan MM Mutsaerts https://orcid.org/0000-0003-0894-0307 ... The cerebellum was used as a reference region to assess non-specific binding (mean (SD) ROI size = 131.2 (28.7) cm 3 ) (Booij et al., 2007) . ... Another explanation for the low correlation is that [ 123 I]FP-CIT is not a selective SERT tracer and our measurements could have also included some DAT binding (Booij et al., 2007) . ...doi:10.1177/0269881119836229 pmid:30887865 pmcid:PMC6572584 fatcat:fwmmbhoqf5geloeljtmprq4rha
« Previous Showing results 1 — 15 out of 780 results